Effect of Ligustrazine Combined with Atorvastatin on Patients with Angina Pectoris of Coronary Heart Disease

YUAN Min; GAO Haijun; ZHA Yuanqiong; WU Qin; LOU Guoliang

doi:10.14033/j.cnki.cfmr.2024.17.005

Abstract：Objective:To investigate the effect of Ligustrazine combined with Atorvastatin on angina pectoris of coronary heart disease.Method:A total of 86 patients with angina pectoris of coronary heart disease admitted to the Post and Telecommunications Hospital of Guizhou Provincial People's Hospital from December 2020 to December 2022 were selected as the study objects and divided into two groups according to random number table method,with 43 cases in each group.The control group was treated with Atorvastatin Calcium Tablets orally,and the observation group was treated with Ligustrazine Phosphate Injection on the basis of the control group.Both groups were treated continuously for 10 d.Angina pectoris attack,cardiac function index,lipid metabolism index and quality of life before and after treatment were compared between the two groups,and adverse reactions between the two groups were recorded.Result:Before treatment,there were no significant differences in duration of angina pectoris attacks,frequency of angina pectoris attacks,visual analogue scale(VAS)score,whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),triglyceride(TG),total cholesterol(TC),brain natriuretic peptide(BNP),C-reactive protein(CRP),the MOS item short from health survey(SF-36)score between the two groups(P>0.05).After 10 d of treatment,duration of angina pectoris attacks in the observation group was shorter than that in the control group,frequency of angina pectoris attacks,VAS score,whole blood high shear viscosity,plasma viscosity,whole blood low shear viscosity,LDL-C,TG,TC,BNP and CRP in the observation group were lower than those in the control group,and HDL-C and SF-36 scores in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Ligustrazine combined with Atorvastatin has a significant effect in the treatment of angina pectoris of coronary heart disease,which can effectively improve the condition of angina pectoris of patients,improve hemorheology,regulate lipid metabolism,improve quality of life,and have high safety.